Pigment and microdermabrasion are working at different depths.
Melanin is made by cells called melanocytes that sit at the base of the epidermis, the bottom of the living outer layer of skin. From there the pigment is passed upward into the cells above. In melasma and in many cases of post-inflammatory hyperpigmentation, pigment also drops into the dermis below, where it is out of reach of anything that works on the surface.
Microdermabrasion works above all of that. Its target is the stratum corneum, the outermost layer of dead, flattened cells, which averaged 9.42 micrometers before treatment in the one imaging study that measured it in living facial skin, in 8 volunteers. That is roughly a tenth the width of a human hair, and it rebuilds within a day or two.
The published depth work confirms how little comes off. In 49 people given a single treatment, no alteration in stratum corneum thickness was detected. In 38 people given eight weekly sessions, biopsy-measured epidermal thickness did not change significantly in any group. What the single-treatment study did find was a rapid rise in inflammatory signals and collagen-remodeling enzymes, which is the basis for the argument that whatever benefit exists comes from a healing response rather than from removing pigmented tissue.
That inflammatory response is the same thing that makes darkening a possibility. It is not a neutral mechanism when the problem is pigment.
The single most quoted summary is from an evidence review, and it is not encouraging: microdermabrasion can produce changes in the dermal matrix and improve skin contour irregularities, and may help deliver certain medicines, but its role in the treatment of dyschromias and acne vulgaris is limited. Dyschromia is the medical word for uneven color.
Here is the detail behind that.
The histology study, 38 people. Four groups, one of them melasma, all given eight microdermabrasion sessions a week apart with biopsies at baseline, after the fourth and after the eighth. Clinical improvement was graded mild to moderate in the melasma group and mild only in the sun-damage group. Biopsy showed decreased melanization and a more regular distribution of melanosomes in the melasma group. Measured epidermal thickness did not change significantly.
The 2001 study, 14 people. Twelve to fourteen weeks of treatment. Patients rated roughness, mottled pigmentation and overall appearance as significantly improved, though wrinkles were not. Those were patient ratings in an unblinded study, which is the weakest kind of endpoint. Biopsy of chronically treated skin showed decreased melanization.
The colorimetry study, 16 women. Once weekly for six weeks alongside a cleanser and lotion regimen. Fine wrinkles, dullness, pigmentation and large pores improved significantly by the third treatment, and instrument-measured brightness rose while yellowness fell. There was no untreated control group and the concurrent skincare cannot be separated out.
Eleven women awaiting abdominoplasty had a 25 square centimeter test area treated with crystal microdermabrasion at maximum crystal flow, 200 mmHg suction, eight passes, with the opposite side used as an untreated control. Between one and five weekly sessions were given, and tissue was sampled from day 0 to day 132.
Alongside increased epidermal thickness and an initial rise in collagen synthesis, the authors recorded that a mild to marked hyperpigmentation was observed and remained for a variable period.
This is the single best published evidence that microdermabrasion can induce pigment rather than remove it, because it was documented on biopsy in a design where each participant acted as her own control. The skin types of the participants are not stated, so it cannot be read as a finding specifically about darker skin. What it does show is that aggressive settings on abdominal skin produced lasting darkening.
That study used eight passes at maximum flow. It is a reminder that the depth reached in microdermabrasion is set by the operator, not by the machine, and that the aggressive end of the range is where pigment problems live.
The best-designed one is a delivery study, not a pigment treatment study. Thirty women with melasma, all Fitzpatrick IV or V, had three passes of microdermabrasion on one side of the face only, and then a 70 percent glycolic acid peel applied to the whole face. Melasma scores fell significantly overall, and the side that had been pretreated with microdermabrasion fell significantly further than the peel-only side, with a p value of 0.041.
This is the strongest pigment evidence in skin of color in the whole field, and it is genuinely useful. But read what it shows: microdermabrasion improved the performance of a strong acid peel. It was a penetration enhancer. Nobody in that study had microdermabrasion as their pigment treatment.
The most-quoted melasma result stacks three treatments at once. Twenty-seven women with phototypes II to V and melasma that had failed previous treatment received microdermabrasion followed immediately by a low-fluence Q-switched Nd:YAG laser, repeated every four weeks, plus daily broad-spectrum sunscreen and topical hydroquinone with either tretinoin or vitamin C. After an average of 2.6 treatments, 22 of 27 achieved more than 75 percent clearance on blinded photographic grading, and 11 of 27 achieved more than 95 percent.
Those are impressive numbers, and there is no arm of that study that isolates microdermabrasion. Three active treatments were given simultaneously, one of them a prescription lightening regimen with strict sun protection, which is itself an effective melasma treatment. This study cannot attribute any of that benefit to the microdermabrasion step. It also reported that 4 of the 27 had a temporary worsening of their melasma after sun exposure.
Three recent positive studies share a single design problem. A 12-week study of 18 people with Fitzpatrick I to IV and facial hyperpigmentation reported significant improvement after six diamond-tip treatments every two weeks with a brightening infusion serum, plus a daily at-home brightening serum and dark spot cream. It was open-label, single-arm, with no control group, and funded by the device manufacturer. It also excluded Fitzpatrick V and VI entirely. One of its reported findings, that the melasma score improved by day 3, is not biologically plausible as pigment clearance; three days is far too short for melanin to be cleared, and a change that fast is more consistent with a surface or optical effect.
Two companion studies from the same manufacturer, of 16 and 29 people, have the same shape: open-label, no control arm, device combined with take-home topicals, authors employed by or affiliated with the manufacturer. That is not an accusation of bad faith. It is a description of a design that reliably produces positive results and cannot separate the device from the products used alongside it.
Melasma is the diagnosis where this treatment is most likely to be recommended and most likely to backfire.
Melasma is a chronic condition of symmetrical brown or gray-brown patches, usually on the cheeks, forehead and upper lip, driven by sun, heat, hormones and genetics. Two things about it matter here.
First, it is easily aggravated by irritation. Anything that inflames the skin can provoke more pigment. That is why the study above recorded flares after sun exposure even in women whose melasma was otherwise clearing, and why a review of post-inflammatory hyperpigmentation after cosmetic procedures identifies a history of melasma as a risk factor and states the position bluntly: a risk and benefit assessment of the cosmetic procedure is required, and no risky procedure in patients at risk. That review also advises against procedures in summer or on suntanned skin, and names excessive treatment intensity as a contributing technical error.
Second, melasma relapses. Even successful treatments tend to be maintenance rather than cure, and results measured at 12 weeks in melasma studies often reverse afterward.
The best available data for microdermabrasion in melasma is mild to moderate improvement in a 38-person study, and a marginal advantage as a pretreatment before a strong peel in 30 women with Fitzpatrick IV and V skin. That is a thin basis for a course of treatments on a condition that punishes irritation.
Post-inflammatory hyperpigmentation, meaning dark patches left behind after the skin has been irritated, is the risk that matters here, and it is more common in deeper skin tones.
The general risk framing is well established across cosmetic procedures: post-inflammatory hyperpigmentation occurs more frequently in people with darker skin, in Asian populations, and in women with a history of melasma. The evidence behind that framing comes mostly from peels and lasers rather than from microdermabrasion, and it should not be used to assign a number to this procedure.
And there is no number to assign. No published study reports a rate of post-inflammatory hyperpigmentation after microdermabrasion in any skin type. That absence is a real finding rather than an oversight in the reading, and anyone quoting a percentage for this is inventing it.
The representation problem is worse than that. Across the microdermabrasion and hydrodermabrasion studies with documented skin types, the ranges run II to V, IV to V, I to IV and I to V; the one exception is a manufacturer-run hydradermabrasion study of 29 women that enrolled Fitzpatrick II to VI without reporting outcomes separately for the deepest skin tones. Outside that single study, Fitzpatrick VI is effectively absent from this literature. If you have deeply pigmented skin, this procedure has not really been studied on you.
The one reassuring signal is the split-face study of 30 women with Fitzpatrick IV and V skin, where microdermabrasion before a glycolic peel was described as improving the outcome effectively and safely, with no darkening reported. That is a single study without long-term follow-up in its published summary.
Practically, if you have Fitzpatrick IV to VI skin and pigment you want treated, the questions to ask are what settings will be used, how many passes, whether a test area can be done first, and what the plan is if the treated area darkens.
None of this makes microdermabrasion useless. It makes it a poor first choice for pigment. These are the things with more evidence behind them, and all of them are worth discussing with a dermatologist rather than buying off a treatment menu.
Daily broad-spectrum sun protection. It appears in every successful pigment protocol in the literature, including the ones above, and it is the only part that also prevents recurrence.
Topical treatment, usually prescription. The successful melasma protocols in darker skin almost all include priming or concurrent treatment with hydroquinone, often with tretinoin. In the studies where a lightening regimen ran alongside a procedure, it is impossible to rule out that the topical was doing much of the work.
Chemical peels, chosen for skin tone. In a pooled analysis of 10 randomized trials and 3 comparative studies covering 478 melasma patients with darker skin, glycolic acid was favoured over trichloroacetic acid, and both trichloroacetic acid and Jessner's solution were favoured over topical hydroquinone alone. In deeply pigmented skin, superficial salicylic acid peels have the foundational safety data, from a 25-patient study in Fitzpatrick V and VI, and a 90-person randomized trial in Indian patients found salicylic-mandelic peels as effective as glycolic acid and better tolerated.
A laser, for the right kind of spot. For discrete age spots, a randomized split-hand trial in 45 people found a Q-switched 532 nm laser significantly better than a 35 percent acid peel, with darkening afterward in 1 patient in the laser arm versus 4 in the peel arm. Lasers are a different proposition in melasma, where a split-face trial of 18 women found a 1550 nm fractional laser no better than a 15 percent acid peel and the melasma recurring by 12 weeks. In Fitzpatrick IV to VI, intense pulsed light capable of resurfacing and hair removal is specifically advised against because of the risk of both darkening and lightening.
And microdermabrasion as a preparation step. Its best pigment result was as a way of getting a peel to work better. If a clinic offers it as part of a protocol that includes a peel and a topical regimen, that is a defensible use. Sold alone as a pigment treatment, it is not.
No microdermabrasion device is FDA cleared for hyperpigmentation, or for anything else.
These machines are Class I devices, product code GFE, under 21 CFR 878.4820, and are exempt from premarket review subject to the limitations in 21 CFR 878.9. Manual devices were exempted in 1994 and powered devices in 1998. The only two clearances ever granted in that product code, K905046 in 1990 and K963204 in 1996, both predate the exemption, and no currently marketed microdermabrasion machine holds a K-number or an FDA-reviewed indication for pigment or for anything else.
That is not a safety warning. General controls still apply: registration, device listing, manufacturing quality requirements, adverse event reporting, and a prohibition on false or misleading labeling. What it means is that no regulator has assessed whether any of these machines improves pigment. If a clinic tells you a microdermabrasion machine is FDA cleared or FDA approved for dark spots, that is not accurate.